Analytical Data
-
Gene name
Staphylococcus aureus
- Application
-
Biological Activity
Measured by its binding ability in a functional ELISA. Immobilized Protein G at 2μg/mL (100μL/well) can bind Biotinylated Human IgG1. The ED50 for this effect is 0.1099 μg/mL. Measured by its binding ability in a functional ELISA. Immobilized Protein G at 2 μg/mL (100 μL/well) can bind Biotinylated Human IgG1. The ED50 for this effect is 0.1099 μg/mL.
-
Alternative Names
Immunoglobulin G-binding protein G; spg; IgG-binding protein G
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
C-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Molecular Weight
27 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Staphylococcus aureus is a significant pathogenic bacterium responsible for a wide range of infections in humans, ranging from mild skin infections to severe conditions like pneumonia and sepsis. The emergence of antibiotic-resistant strains, particularly Methicillin-resistant Staphylococcus aureus (MRSA), has heightened the need for novel therapeutic strategies and preventive measures. Research on recombinant proteins derived from Staphylococcus aureus focuses on the development of vaccines and targeted therapies. By utilizing recombinant DNA technology, scientists can produce specific antigens that elicit strong immune responses, potentially leading to effective vaccines that can protect against infections. Additionally, these proteins can serve as valuable tools in understanding virulence mechanisms and host-pathogen interactions. The investigation of recombinant proteins also aids in the identification of biomarkers for early diagnosis and monitoring of infections. With the increasing global burden of antibiotic resistance, the ongoing research in this area is crucial for enhancing public health protection and developing innovative solutions to combat Staphylococcus aureus-related diseases.











